Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 2:6:601.
doi: 10.3389/fimmu.2015.00601. eCollection 2015.

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy

Affiliations
Review

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy

Cariad Chester et al. Front Immunol. .

Abstract

There is compelling clinical and experimental evidence to suggest that natural killer (NK) cells play a critical role in the recognition and eradication of tumors. Efforts at using NK cells as antitumor agents began over two decades ago, but recent advances in elucidating NK cell biology have accelerated the development of NK cell-targeting therapeutics. NK cell activation and the triggering of effector functions is governed by a complex set of activating and inhibitory receptors. In the early phases of cancer immune surveillance, NK cells directly identify and lyse cancer cells. Nascent transformed cells elicit NK cell activation and are eliminated. However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. Therapeutic intervention aims to reverse tumor-induced NK cell suppression and sustain NK cells' tumorlytic capacities. Here, we review tumor-NK cell interactions, discuss the mechanisms by which NK cells generate an antitumor immune response, and discuss NK cell-based therapeutic strategies targeting activating, inhibitory, and co-stimulatory receptors.

Keywords: adoptive cell therapy; cancer vaccines; checkpoint blockade; immunotherapy; monoclonal antibody; natural killer cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The major NK cell receptors that are potential immunotherapeutic targets. The transition of the NK cell from quiescence to activation is mediated by a network of activating and inhibitory receptors; it is the integration of the activating and inhibitory signals that determines if the NK cell becomes cytotoxic. Using immunotherapeutic agents to increase activation and decreases inhibitory signaling has the potential to generate NK cells with enhanced tumor lytic capacity. MICA/B, MHC class I chain-related proteins A and B; ULBP, UL16-binding protein; BAG, Bcl2-associated athanogene.

References

    1. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene (2008) 27:5932–43.10.1038/onc.2008.267 - DOI - PubMed
    1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9:503–10.10.1038/ni1582 - DOI - PubMed
    1. Caligiuri MA. Human natural killer cells. Blood (2008) 112:461–9.10.1182/blood-2007-09-077438 - DOI - PMC - PubMed
    1. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood (2001) 97:3146–51.10.1182/blood.V97.10.3146 - DOI - PubMed
    1. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol (2007) 179:89–94.10.4049/jimmunol.179.1.89 - DOI - PubMed